TNM 8 staging is a better prognosticator than TNM 7 for patients with locally advanced oral cavity squamous cell carcinoma treated with surgery and post-operative radiotherapy.


Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192

Informations de publication

Date de publication:
07 2021
Historique:
received: 18 11 2020
revised: 20 03 2021
accepted: 02 04 2021
pubmed: 13 4 2021
medline: 28 7 2021
entrez: 12 4 2021
Statut: ppublish

Résumé

To assess TNM 8 staging in discriminating overall survival (OS) amongst patients with locally advanced oral cavity squamous cell carcinoma (OCSCC) treated with surgery and post-operative radiotherapy (PORT), compared to TNM 7. Data from OCSCC patients treated with surgery and PORT between January 2010 and December 2018 were reviewed. Demographics, tumour characteristics and treatment response data were collected, and patients staged according to both TNM 7 and TNM 8. OS and disease free survival (DFS) were estimated using the Kaplan Meier method. Univariate and multivariable analyses were conducted for factors affecting OS, DFS and early disease recurrence within 12 months. Overall 172 patients were analyzed. Median follow up was 32 months for all patients and 48 months for surviving patients. TNM 8 staging demonstrated significant stratification of OS and DFS amongst the entire cohort, whereas TNM 7 staging did not. On multivariable analysis, TNM 8 stage, performance status (PS) and a positive surgical margin were prognostic for OS. Looking at disease recurrence within 12 months, TNM 8 stage IVB, presence of lymphovascular invasion (LVSI), younger age and lesser smoking history were predictive factors on multivariable analysis. TNM 8 is a good development of its predecessor in terms of predicting survival for patients with locally advanced OCSCC. We have also identified younger age (<60 years) and a smoking history of <10 pack years as risk factors for early disease recurrence, potentially representing a separate biological cohort within OCSCC patients.

Identifiants

pubmed: 33845044
pii: S0167-8140(21)06184-3
doi: 10.1016/j.radonc.2021.04.003
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

54-60

Informations de copyright

Copyright © 2021 Elsevier B.V. All rights reserved.

Auteurs

Khrishanthne Sambasivan (K)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK. Electronic address: Khrishanthne.sambasivan@gstt.nhs.uk.

Isabel Sassoon (I)

Department of Computer Science, Brunel University London, UK.

Selvam Thavaraj (S)

Faculty of Dentistry, Clinical and Orofacial Sciences, King's College London, UK; Head and Neck Pathology, Guy's and St Thomas, NHS Foundation Trust, UK.

Robert Kennedy (R)

Faculty of Dentistry, Clinical and Orofacial Sciences, King's College London, UK.

Gowardhanan Doss (G)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK.

Andriana Michaelidou (A)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK.

Edward Odell (E)

King's College London, UK; Head and Neck Pathology, Guy's and St Thomas, NHS Foundation Trust, UK.

Ann Sandison (A)

Head and Neck Pathology, Guy's and St Thomas, NHS Foundation Trust, UK.

Gillian Hall (G)

King's College London, UK; Head and Neck Pathology, Guy's and St Thomas, NHS Foundation Trust, UK.

Peter Morgan (P)

King's College London, UK; Head and Neck Pathology, Guy's and St Thomas, NHS Foundation Trust, UK.

Lisette Hannah Claire Collins (LHC)

Head and Neck Pathology, Guy's and St Thomas, NHS Foundation Trust, UK.

Andrew Lyons (A)

Head and Neck Surgery Unit, Guy's and St Thomas' NHS Trust, London, UK.

Luke Cascarini (L)

Head and Neck Surgery Unit, Guy's and St Thomas' NHS Trust, London, UK.

Alastair Fry (A)

Head and Neck Surgery Unit, Guy's and St Thomas' NHS Trust, London, UK.

Richard Oakley (R)

Head and Neck Surgery Unit, Guy's and St Thomas' NHS Trust, London, UK.

Ricard Simo (R)

Head and Neck Surgery Unit, Guy's and St Thomas' NHS Trust, London, UK.

Jean-Pierre Jeannon (JP)

Head and Neck Surgery Unit, Guy's and St Thomas' NHS Trust, London, UK.

Imran Petkar (I)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK.

Miguel Reis Ferreira (M)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK; King's College London, UK.

Anthony Kong (A)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK; King's College London, UK.

Mary Lei (M)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK.

Teresa Guerrero Urbano (T)

Department of Clinical Oncology, Guy's and St Thomas, NHS Trust London, UK; King's College London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH